The global hereditary angioedema therapeutics market size was estimated at USD 3.60 billion in 2025 and is projected to reach USD 8.18 billion by 2033, growing at a CAGR of 10.43% from 2026 to 2033. The global hereditary angioedema therapeutics market is expanding due to increasing diagnosis rates and greater clinical awareness of rare genetic disorders.
Improved access to specialized testing has enabled earlier identification of patients, which supports timely treatment initiation. The availability of targeted therapies that address underlying disease pathways has strengthened treatment outcomes and patient confidence. Pharmaceutical innovation has introduced convenient administration options, including subcutaneous and oral formulations, which improve adherence. Rising prevalence reporting across developed and emerging regions continues to create sustained demand for effective therapies.
Advancements in biologics and novel drug classes represent another major growth driver for the market. Long-acting prophylactic therapies have reduced attack frequency and improved quality of life for patients, which has increased adoption among physicians. Oral kallikrein inhibitors and gene-targeted approaches under development are expanding the future treatment landscape. Strong clinical trial activity and regulatory approvals have accelerated commercialization timelines for innovative therapies. For instance, December 2025, HCPLive reported that the U.S. Food and Drug Administration had approved three new hereditary angioedema treatments in 2025 over three months, including garadacimab gxii, Andembry, in June, sebetralstat, Ekterly, in July, and donidalorsen, Dawnzera, in August, in a disease affecting about 1 in 50,000 people globally and nearly 6,000 in the United States. Prior to these approvals, 9 therapies were available, increasing to 12 by 2026, reflecting the expansion of oral and injectable options. Strategic collaborations between biotechnology firms and larger pharmaceutical companies have further enhanced research capabilities and global distribution reach.
Healthcare infrastructure improvements and the expansion of specialty care networks are further contributing to market growth. Increased involvement of immunologists and rare disease specialists has strengthened disease management standards and treatment utilization. Patient advocacy initiatives and education programs have encouraged treatment uptake and long-term therapy compliance. Favorable reimbursement coverage in several regions has improved patient access to high-cost biologic treatments. For instance, in December 2025, Rare Disease Advisor reported that the U.S. Food and Drug Administration had approved berotralstat, marketed as ORLADEYO, as the first oral plasma kallikrein inhibitor prophylactic therapy for hereditary angioedema in children aged 2 to 11 years, extending prior approval for patients 12 years and older. The pediatric approval was based on the APeX P trial involving 29 patients aged 2 to 11 years, 48.3 percent female, with a mean age of 8 years and a mean onset at 2 years, demonstrating sustained reductions in monthly attack rates and a peak median concentration of 3.9 hours, range 0.9 to 6.0 hours. Growing investment in rare disease research continues to support innovation and competitive market expansion.
This product will be delivered within 1-3 business days.
Improved access to specialized testing has enabled earlier identification of patients, which supports timely treatment initiation. The availability of targeted therapies that address underlying disease pathways has strengthened treatment outcomes and patient confidence. Pharmaceutical innovation has introduced convenient administration options, including subcutaneous and oral formulations, which improve adherence. Rising prevalence reporting across developed and emerging regions continues to create sustained demand for effective therapies.
Advancements in biologics and novel drug classes represent another major growth driver for the market. Long-acting prophylactic therapies have reduced attack frequency and improved quality of life for patients, which has increased adoption among physicians. Oral kallikrein inhibitors and gene-targeted approaches under development are expanding the future treatment landscape. Strong clinical trial activity and regulatory approvals have accelerated commercialization timelines for innovative therapies. For instance, December 2025, HCPLive reported that the U.S. Food and Drug Administration had approved three new hereditary angioedema treatments in 2025 over three months, including garadacimab gxii, Andembry, in June, sebetralstat, Ekterly, in July, and donidalorsen, Dawnzera, in August, in a disease affecting about 1 in 50,000 people globally and nearly 6,000 in the United States. Prior to these approvals, 9 therapies were available, increasing to 12 by 2026, reflecting the expansion of oral and injectable options. Strategic collaborations between biotechnology firms and larger pharmaceutical companies have further enhanced research capabilities and global distribution reach.
Healthcare infrastructure improvements and the expansion of specialty care networks are further contributing to market growth. Increased involvement of immunologists and rare disease specialists has strengthened disease management standards and treatment utilization. Patient advocacy initiatives and education programs have encouraged treatment uptake and long-term therapy compliance. Favorable reimbursement coverage in several regions has improved patient access to high-cost biologic treatments. For instance, in December 2025, Rare Disease Advisor reported that the U.S. Food and Drug Administration had approved berotralstat, marketed as ORLADEYO, as the first oral plasma kallikrein inhibitor prophylactic therapy for hereditary angioedema in children aged 2 to 11 years, extending prior approval for patients 12 years and older. The pediatric approval was based on the APeX P trial involving 29 patients aged 2 to 11 years, 48.3 percent female, with a mean age of 8 years and a mean onset at 2 years, demonstrating sustained reductions in monthly attack rates and a peak median concentration of 3.9 hours, range 0.9 to 6.0 hours. Growing investment in rare disease research continues to support innovation and competitive market expansion.
Global Hereditary Angioedema Therapeutics Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, the analyst has segmented the global hereditary angioedema therapeutics market based on treatment, end use, route of administration, and region:Treatment Outlook (Revenue, USD Million, 2021-2033)
- C1-Inhibitor Concentrates
- Bradykinin B2 Receptor Antagonist
- Kallikrein Inhibitor
- Others
End use Outlook (Revenue, USD Million, 2021-2033)
- Prophylaxis
- On-demand
Route of Administration Outlook (Revenue, USD Million, 2021-2033)
- Intravenous
- Subcutaneous
- Oral
Regional Outlook (Revenue, USD Million, 2021-2033)
- North America
- U.S.
- Canada
- Mexico
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
- Asia Pacific
- Japan
- China
- India
- Australia
- South Korea
- Thailand
- Latin America
- Brazil
- Argentina
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Kuwait
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listings for you to stay ahead of the curve
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Hereditary Angioedema Therapeutics Market Variables, Trends, & Scope
Chapter 4. Hereditary Angioedema Therapeutics Market: Treatment Business Analysis
Chapter 5. Hereditary Angioedema Therapeutics Market: End Use Business Analysis
Chapter 6. Hereditary Angioedema Therapeutics Market: Route of Administration Business Analysis
Chapter 7. Hereditary Angioedema Therapeutics Market: Regional Estimates & Trend Analysis
Chapter 8. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
- BioCryst Pharmaceuticals, Inc.
- Ionis Pharmaceuticals
- CSL
- Attune Pharmaceuticals
- Adverum Biotechnologies, Inc.
- KalVista Pharmaceuticals, Inc.
- Takeda Pharmaceutical Company Limited
- Pharming
- Sanofi
- Pharvaris B.V.
- Arrowhead Pharmaceuticals, Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 150 |
| Published | March 2026 |
| Forecast Period | 2025 - 2033 |
| Estimated Market Value ( USD | $ 3.6 Billion |
| Forecasted Market Value ( USD | $ 8.18 Billion |
| Compound Annual Growth Rate | 10.4% |
| Regions Covered | Global |
| No. of Companies Mentioned | 11 |
